Articles written by Vandana Singh - Benzinga

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

Dallas Fed Flags Deepening Factory Gloom: Is Texas Warning Of Something Bigger?

SEO-Optimized Meta Description (Under 156 Characters): Texas manufacturing conditions worsened in April as business sentiment plunged, tariff fears grew, and price pressures surged, Dallas Fed survey shows.

Pfizer CEO Albert Bourla Emphasizes National Security In US Drug Manufacturing

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations and national security concerns.

Scotts Miracle Gro Pulls Hawthorne Guidance, Citing Uncertain Environment In Cannabis Industry, Stock Falls

Scotts Miracle-Gro Q2 results show margin gains and EBITDA growth despite sales decline; 2025 guidance maintained for US consumer segment.

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new and existing drug products.

Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline

Humana beat Q1 EPS estimates with $11.58, reaffirmed 2025 guidance, and outlined margin goals despite a drop in Medicare Advantage membership.

GE HealthCare Blames Tariffs For Lowering 2025 Profit Outlook, Initiates Stock Buyback

GE HealthCare beat Q1 expectations with strong EPS, revenue, and order growth, while revising 2025 guidance due to tariffs and cash flow impacts.

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to close in H2 2025.

Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales

GSK beat Q1 estimates with $9.46 billion in sales and $1.13 EPS, driven by strong Specialty Medicines and meningitis vaccine performance.

EXCLUSIVE: Silo Pharma's Investigational Ketamine Implant Hits All Endpoints In Pain Study In Animal Models

Silo Pharma reported positive preclinical results for its ketamine-based implant SP-26, designed to treat chronic pain and fibromyalgia.

Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy

FDA approves Zevaskyn as the first cell-based gene therapy for RDEB wounds after strong results in pivotal and long-term studies.

Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides

Regeneron boosts antibody profits with higher Dupixent sales and expands biologics production via FUJIFILM Diosynth partnership.

Goldman Sachs Downgrades Avantor As Shares Spiral 60% Since 2021: 'We Wrongly Assumed...'

Avantor missed Q1 sales estimates and faced multiple analyst downgrades as concerns mount over growth, competition, and product performance.

AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis

AbbVie wins FDA approval for Rinvoq in giant cell arteritis after strong Phase 3 results and a 57.2% year-over-year sales increase in Q1.

Novartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance

Novartis raises 2025 sales and profit forecast as key drugs drive strong Q1 results; core operating income up 23% to $5.6 billion on higher net sales.

Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform

Hims & Hers partners with Novo Nordisk to offer Wegovy access online with clinical support, expanding its weight loss care and revenue strategy.

Pfizer's Covid Windfall Shrinks, Expands Cost-Cutting Efforts

Pfizer beats Q1 EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts the Truqap trial in prostate cancer.

CORRECTION: EXCLUSIVE: Nuvve Acquires Fermata Energy Assets, Says Deal Adds Resilience Amid Evolving Tariff Policies

Nuvve forms Fermata 2.0 after acquiring Fermata Energy to boost V2G services, cut costs, and expand U.S. energy hardware and software offerings.

Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications

A lawsuit claims Eli Lilly, Johnson & Johnson, and Kaiser Permanente failed to warn consumers about breast cancer risks linked to their antipsychotic drugs Risperdal and Zyprexa.